Floatz logo

stp705

Abdominal Obesity

SirnaomicsPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Abdominal Obesity cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
UMC Utrecht
Phase 4BBB
Moxonidine
Baker Heart and Diabetes Institute
Phase 4BB
Elafibranor
Genfit
Phase 2BB
Irbesartan
Baker Heart and Diabetes Institute
Phase 4BB
UMBELLATINE
China National Center for Cardiovascular Diseases
Phase 4BB

View all 27 →

Same molecule, other indications

stp705 is also rated in:

Liver MetastasesDormant
CC
Indicative ·
42 / 100
View asset →
cholangiocarcinomaDormant
CC
Indicative ·
42 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →